Do analysts rate GTBP or ALPS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ALPS Group Inc Ordinary Share 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is GTBP or ALPS more profitable?

ALPS Group Inc Ordinary Share's return on equity of 0.00% beat GT Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets GT Biopharma N/A -213.16% -150.61% ALPS Group Inc Ordinary Share N/A N/A N/A

Do analysts prefer TCRX or GTBP?

TScan Therapeutics presently has a consensus price target of $4.67, suggesting a potential upside of 1,158.20%. Given TScan Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe TScan Therapeutics is more favorable than GT Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TScan Therapeutics 1 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.29 GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer GTBP or TIL?

Instil Bio has a consensus target price of $66.00, indicating a potential upside of 761.62%. Given Instil Bio's stronger consensus rating and higher probable upside, analysts plainly believe Instil Bio is more favorable than GT Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Instil Bio 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has better valuation and earnings, GTBP or TIL?

Instil Bio is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GT Biopharma N/A N/A -$28.35M -$5.90 N/A Instil Bio N/A N/A -$71.37M -$4.47 N/A

Is GTBP or TIL more profitable?

Instil Bio's return on equity of -26.78% beat GT Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets GT Biopharma N/A -213.16% -150.61% Instil Bio N/A -26.78% -14.89%

Do analysts rate MCRB or GTBP?

Seres Therapeutics presently has a consensus price target of $17.00, indicating a potential upside of 201.42%. Given Seres Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Seres Therapeutics is more favorable than GT Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Seres Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer BKHA or GTBP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Black Hawk Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, BKHA or GTBP?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Black Hawk Acquisition N/A N/A N/A N/A N/A GT Biopharma N/A N/A -$28.35M -$5.90 N/A

Is BKHA or GTBP more profitable?

Black Hawk Acquisition's return on equity of 0.00% beat GT Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Black Hawk Acquisition N/A N/A N/A GT Biopharma N/A -213.16% -150.61%

GT Biopharma (GTBP) Competitors

$0.25 -0.03 (-10.81%)

As of 09/3/2026 04:00 PM Eastern

Compare

GTBP vs. ALPS, TCRX, TIL, MCRB, and BKHA

Should you buy GT Biopharma stock or one of its competitors? GT Biopharma's main competitors and comparable companies include ALPS Group Inc Ordinary Share (ALPS), TScan Therapeutics (TCRX), Instil Bio (TIL), Seres Therapeutics (MCRB), and Black Hawk Acquisition (BKHA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does GT Biopharma compare to ALPS Group Inc Ordinary Share?

GT Biopharma (NASDAQ:GTBP) and ALPS Group Inc Ordinary Share (NASDAQ:ALPS) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

8.2% of GT Biopharma shares are held by institutional investors. Comparatively, 27.9% of ALPS Group Inc Ordinary Share shares are held by institutional investors. 1.2% of GT Biopharma shares are held by insiders. Comparatively, 25.5% of ALPS Group Inc Ordinary Share shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

ALPS Group Inc Ordinary Share's return on equity of 0.00% beat GT Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GT Biopharma	N/A	-213.16%	-150.61%
ALPS Group Inc Ordinary Share	N/A	N/A	N/A

ALPS Group Inc Ordinary Share has higher revenue and earnings than GT Biopharma. GT Biopharma is trading at a lower price-to-earnings ratio than ALPS Group Inc Ordinary Share, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GT Biopharma	N/A	N/A	-$28.35M	-$5.90	N/A
ALPS Group Inc Ordinary Share	$4.86M	13.01	-$2.01M	$0.33	1.15

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ALPS Group Inc Ordinary Share	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

GT Biopharma has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market. Comparatively, ALPS Group Inc Ordinary Share has a beta of -0.1, suggesting that its share price is 110% less volatile than the broader market.

In the previous week, ALPS Group Inc Ordinary Share's average media sentiment score of 0.00 beat GT Biopharma's score of -0.75 indicating that ALPS Group Inc Ordinary Share is being referred to more favorably in the news media.

Company	Overall Sentiment
GT Biopharma	Negative
ALPS Group Inc Ordinary Share	Neutral

Summary

ALPS Group Inc Ordinary Share beats GT Biopharma on 9 of the 10 factors compared between the two stocks.

How does GT Biopharma compare to TScan Therapeutics?

TScan Therapeutics (NASDAQ:TCRX) and GT Biopharma (NASDAQ:GTBP) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

TScan Therapeutics presently has a consensus price target of $4.67, suggesting a potential upside of 1,158.20%. Given TScan Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe TScan Therapeutics is more favorable than GT Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TScan Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

GT Biopharma has lower revenue, but higher earnings than TScan Therapeutics. TScan Therapeutics is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TScan Therapeutics	$10.32M	2.44	-$129.77M	-$0.91	N/A
GT Biopharma	N/A	N/A	-$28.35M	-$5.90	N/A

GT Biopharma has a net margin of 0.00% compared to TScan Therapeutics' net margin of -1,655.35%. TScan Therapeutics' return on equity of -108.72% beat GT Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TScan Therapeutics	-1,655.35%	-108.72%	-54.47%
GT Biopharma	N/A	-213.16%	-150.61%

TScan Therapeutics has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market. Comparatively, GT Biopharma has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market.

82.8% of TScan Therapeutics shares are owned by institutional investors. Comparatively, 8.2% of GT Biopharma shares are owned by institutional investors. 6.3% of TScan Therapeutics shares are owned by company insiders. Comparatively, 1.2% of GT Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, TScan Therapeutics had 5 more articles in the media than GT Biopharma. MarketBeat recorded 5 mentions for TScan Therapeutics and 0 mentions for GT Biopharma. TScan Therapeutics' average media sentiment score of -0.61 beat GT Biopharma's score of -0.75 indicating that TScan Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
TScan Therapeutics	Negative
GT Biopharma	Negative

Summary

TScan Therapeutics beats GT Biopharma on 12 of the 15 factors compared between the two stocks.

How does GT Biopharma compare to Instil Bio?

GT Biopharma (NASDAQ:GTBP) and Instil Bio (NASDAQ:TIL) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability, media sentiment and institutional ownership.

Instil Bio's return on equity of -26.78% beat GT Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GT Biopharma	N/A	-213.16%	-150.61%
Instil Bio	N/A	-26.78%	-14.89%

Instil Bio has a consensus target price of $66.00, indicating a potential upside of 761.62%. Given Instil Bio's stronger consensus rating and higher probable upside, analysts plainly believe Instil Bio is more favorable than GT Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Instil Bio's average media sentiment score of 0.00 beat GT Biopharma's score of -0.75 indicating that Instil Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
GT Biopharma	Negative
Instil Bio	Neutral

Instil Bio is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GT Biopharma	N/A	N/A	-$28.35M	-$5.90	N/A
Instil Bio	N/A	N/A	-$71.37M	-$4.47	N/A

GT Biopharma has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market. Comparatively, Instil Bio has a beta of 1.91, meaning that its share price is 91% more volatile than the broader market.

8.2% of GT Biopharma shares are owned by institutional investors. Comparatively, 60.6% of Instil Bio shares are owned by institutional investors. 1.2% of GT Biopharma shares are owned by company insiders. Comparatively, 47.0% of Instil Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Instil Bio beats GT Biopharma on 9 of the 11 factors compared between the two stocks.

How does GT Biopharma compare to Seres Therapeutics?

Seres Therapeutics (NASDAQ:MCRB) and GT Biopharma (NASDAQ:GTBP) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership and risk.

Seres Therapeutics has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market. Comparatively, GT Biopharma has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market.

In the previous week, Seres Therapeutics had 3 more articles in the media than GT Biopharma. MarketBeat recorded 3 mentions for Seres Therapeutics and 0 mentions for GT Biopharma. Seres Therapeutics' average media sentiment score of 0.22 beat GT Biopharma's score of -0.75 indicating that Seres Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Seres Therapeutics	Neutral
GT Biopharma	Negative

59.3% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 8.2% of GT Biopharma shares are owned by institutional investors. 5.2% of Seres Therapeutics shares are owned by company insiders. Comparatively, 1.2% of GT Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Seres Therapeutics presently has a consensus price target of $17.00, indicating a potential upside of 201.42%. Given Seres Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Seres Therapeutics is more favorable than GT Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Seres Therapeutics has higher revenue and earnings than GT Biopharma. Seres Therapeutics is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$790K	71.75	$5.70M	-$2.43	N/A
GT Biopharma	N/A	N/A	-$28.35M	-$5.90	N/A

GT Biopharma has a net margin of 0.00% compared to Seres Therapeutics' net margin of -1,192.94%. Seres Therapeutics' return on equity of -114.82% beat GT Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	-1,192.94%	-114.82%	-34.15%
GT Biopharma	N/A	-213.16%	-150.61%

Summary

Seres Therapeutics beats GT Biopharma on 12 of the 15 factors compared between the two stocks.

How does GT Biopharma compare to Black Hawk Acquisition?

Black Hawk Acquisition (NASDAQ:BKHA) and GT Biopharma (NASDAQ:GTBP) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Hawk Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Black Hawk Acquisition has a beta of 0.04, suggesting that its share price is 96% less volatile than the broader market. Comparatively, GT Biopharma has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market.

In the previous week, Black Hawk Acquisition's average media sentiment score of 0.00 beat GT Biopharma's score of -0.75 indicating that Black Hawk Acquisition is being referred to more favorably in the media.

Company	Overall Sentiment
Black Hawk Acquisition	Neutral
GT Biopharma	Negative

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Hawk Acquisition	N/A	N/A	N/A	N/A	N/A
GT Biopharma	N/A	N/A	-$28.35M	-$5.90	N/A

8.2% of GT Biopharma shares are held by institutional investors. 1.2% of GT Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Black Hawk Acquisition's return on equity of 0.00% beat GT Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Hawk Acquisition	N/A	N/A	N/A
GT Biopharma	N/A	-213.16%	-150.61%

Summary

Black Hawk Acquisition and GT Biopharma tied by winning 3 of the 6 factors compared between the two stocks.

Get GT Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GTBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GTBP vs. The Competition

Export

Metric	GT Biopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$12.77M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-0.04	12.66	273.29	25.38
Price / Sales	N/A	1,309.08	613.45	97.56
Price / Cash	18.92	106.87	77.82	52.26
Price / Book	3.16	16.29	12.89	6.14
Net Income	-$28.35M	-$22.72M	$3.47B	$349.01M
7 Day Performance	-15.87%	0.34%	0.60%	-0.27%
1 Month Performance	-22.60%	8.52%	5.73%	0.68%
1 Year Performance	-72.83%	52.66%	25.35%	14.84%

GT Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GTBP GT Biopharma	0.1016 of 5 stars	$0.25 -10.8%	N/A	-73.1%	$12.77M	N/A	N/A	8	High Trading Volume
ALPS ALPS Group Inc Ordinary Share	0.5647 of 5 stars	$0.31 -0.1%	N/A	N/A	$52.38M	$4.86M	0.95	N/A	Gap Up
TCRX TScan Therapeutics	2.9096 of 5 stars	$0.80 -0.5%	$6.00 +654.1%	-80.2%	$52M	$7.11M	N/A	100	Analyst Downgrade
TIL Instil Bio	1.7925 of 5 stars	$7.60 -2.7%	$66.00 +768.4%	-73.6%	$51.53M	N/A	N/A	410
MCRB Seres Therapeutics	2.5257 of 5 stars	$5.03 +7.9%	$17.00 +238.0%	-69.5%	$50.55M	$790K	N/A	330	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GTBP) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GT Biopharma (GTBP) Competitors

GTBP vs. ALPS, TCRX, TIL, MCRB, and BKHA

How does GT Biopharma compare to ALPS Group Inc Ordinary Share?

Summary

How does GT Biopharma compare to TScan Therapeutics?

Summary

How does GT Biopharma compare to Instil Bio?

Summary

How does GT Biopharma compare to Seres Therapeutics?

Summary

How does GT Biopharma compare to Black Hawk Acquisition?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GTBP vs. The Competition

GT Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GT Biopharma (GTBP) Competitors

GTBP vs. ALPS, TCRX, TIL, MCRB, and BKHA

How does GT Biopharma compare to ALPS Group Inc Ordinary Share?

Do institutionals & insiders have more ownership in GTBP or ALPS?

Is GTBP or ALPS more profitable?

Which has stronger earnings and valuation, GTBP or ALPS?

Do analysts rate GTBP or ALPS?

Which has more volatility & risk, GTBP or ALPS?

Does the media favor GTBP or ALPS?

Summary

How does GT Biopharma compare to TScan Therapeutics?

Do analysts prefer TCRX or GTBP?

Which has higher valuation & earnings, TCRX or GTBP?

Is TCRX or GTBP more profitable?

Which has more risk & volatility, TCRX or GTBP?

Do institutionals and insiders have more ownership in TCRX or GTBP?

Does the media refer more to TCRX or GTBP?

Summary

How does GT Biopharma compare to Instil Bio?

Is GTBP or TIL more profitable?

Do analysts prefer GTBP or TIL?

Does the media favor GTBP or TIL?

Which has better valuation and earnings, GTBP or TIL?

Which has more volatility & risk, GTBP or TIL?

Do insiders and institutionals hold more shares of GTBP or TIL?

Summary

How does GT Biopharma compare to Seres Therapeutics?

Which has more volatility & risk, MCRB or GTBP?

Does the media refer more to MCRB or GTBP?

Do institutionals & insiders believe in MCRB or GTBP?

Do analysts rate MCRB or GTBP?

Which has preferable valuation and earnings, MCRB or GTBP?

Is MCRB or GTBP more profitable?

Summary

How does GT Biopharma compare to Black Hawk Acquisition?

Do analysts prefer BKHA or GTBP?

Which has more risk & volatility, BKHA or GTBP?

Does the media prefer BKHA or GTBP?

Which has better earnings and valuation, BKHA or GTBP?

Do institutionals and insiders believe in BKHA or GTBP?

Is BKHA or GTBP more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GTBP vs. The Competition

GT Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools